Vancouver-based Aspect Biosystems has secured $79 million in federal funding toward a $280 million project to advance its 3D-printed tissue therapies. Supported through the Strategic Response Fund, the initiative will enhance clinical development and expand biomanufacturing capabilities for cellular medicines.
Aspect, a University of British Columbia spinout, develops bioprinted tissues using living cells and biomaterials to repair damaged organs. The company will contribute the remaining $201 million. Chief executive Tamer Mohamed said the investment supports its transition toward clinical-stage development. The project builds on prior public and private funding, including partnerships with Novo Nordisk.
Want to know more? Check out the source code on Techcouver.com.